Randomized trial · people
Tesamorelin: no change in glucose control in type 2 diabetes
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with type 2 diabetes, 12 weeks of tesamorelin did not change insulin response or blood sugar control compared with placebo.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 53
- Published
- 2017
- Journal
- PLoS One
What they tested
The team tested whether tesamorelin changes insulin sensitivity or blood sugar control in people with type 2 diabetes.
How the study was done
A randomized, placebo-controlled trial at several centers in 53 patients with type 2 diabetes, run for 12 weeks. Patients got placebo (a dummy treatment), 1 mg tesamorelin or 2 mg tesamorelin.

What they found
The main outcome was relative insulin response after drinking glucose. It did not differ significantly between the groups over 12 weeks. At week 12, fasting glucose, HbA1c (a measure of average blood sugar over the past few months) and overall diabetes control were also not significantly different, and changes to diabetes medicines were similar across groups. In the 2 mg arm, total cholesterol fell by 0.3±0.6 mmol/L and non-HDL cholesterol by 0.3±0.5 mmol/L from baseline, a significant drop compared with placebo (p<0.05), and no patient left the study because of losing diabetes control.
What it doesn’t show
The trial was small and lasted only 12 weeks, so it does not show longer-term effects on blood sugar. It included only people with type 2 diabetes.
The paper
Clemmons et al. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017.
The compound
More studies on Tesamorelin
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyMeta-analysis · people · 2026
- Tesamorelin shifted liver gene activity in HIV-related fatty liverRandomized trial · people · 2020
- Tesamorelin: denser, larger trunk muscles at 26 weeks in HIVRandomized trial · people · 2019
- Tesamorelin cut visceral and liver fat over 6 months in HIV patientsRandomized trial · people · 2014
- Tesamorelin had little effect on simvastatin and ritonavir levelsRandomized trial · people · 2013
- Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeksRandomized trial · people · 2010
- Every study on Tesamorelin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.